Many of them expressed disappointment that none of the island's 58 doctors took up an invitation to attend the meeting and hear about the science behind the treatment.
'It is astonishing that the medical profession does not appear to be interested in learning about this important treatment when it is benefiting people in 40 countries,' said a Guernsey-based biochemist in the audience.
The audience heard from oncologist and National Cancer Institute medic Professor Marco Ruggiero that the effectiveness of the protein, which is available in other countries around the world, including on prescription, has been investigated and endorsed in 90 international science papers.
Immuno Biotech, the Guernsey company behind the production of GcMAF and research into its uses, wants to create a clinic here.
'We have identified the island as the right size population, in a good location and with risk factors that interest us. Cancer rates are higher than the national average, probably due to radon gas in the granite and the nearby nuclear plant. Creating a clinic here would enable us to give GcMAF to local people free of charge as part of our work,' said CEO David Noakes, pictured.